在患有晚期肝硬化病的患者中,呈现出正常胰岛素样生长因子-1水平的巨病
Ciara Kilcoyne1, Kevin Burke2, Michael W O'Reilly2,3
1Department of Endocrinology, Beaumont Hospital, Dublin 9, Leinster, Ireland ciarakilcoyne@gmail.com.
BMJ case reports
|February 19, 2026
概括
这一案例凸显了肝硬化如何通过降低胰岛素类生长因子-1 (IGF-1) 水平来掩盖缩症. 诊断需要临床评估和生长激素 (GH) 测试,特别是在肝移植正常化IGF-1之后.
科学领域:
- 内分泌学 在内分泌学.
- 肝病学 肝病学是一种肝病学.
- 在瘤学瘤学.
背景情况:
- 巨症是一种罕见的疾病,由多余的生长激素 (GH) 引起.
- 胰岛素样生长因子-1 (IGF-1) 是GH作用的关键调解者.
- 肝硬化可以影响GH/IGF-1轴调节.
研究的目的:
- 为了呈现一个由肝硬化掩盖的壮病病例.
- 强调所需的诊断挑战和临床判断.
- 为了说明肝脏在GH/IGF-1轴中的作用.
主要方法:
- 临床表现和生物化学评估.
- 增长激素 (GH) 和IGF-1水平的评估.
- 通过口服葡萄糖耐受性测试 (OGTT) 确认诊断.
主要成果:
- 患者呈现了壮症症状和GH升高,但由于肝硬化导致的IGF-1正常.
- 通过临床怀疑和OGTT期间GH非抑制,诊断得到了证实.
- 肝移植后,IGF-1水平正常化,证实了活跃的壮病.
结论:
- 肝硬化可以导致虚假正常的IGF-1水平,掩盖壮症.
- 临床评估和GH检测对于在特定情况下诊断壮症至关重要.
- 肝脏在维持GH/IGF-1平衡方面发挥着至关重要的作用.
相关概念视频
Hypoglycemia and Glucagon
1.3K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K
Type I Diabetes III: Clinical Manifestations
26
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the...
26
Type II Diabetes II: Pathophysiology
28
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
28
Hyperglycemia
25
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose...
25
Cirrhosis I: Introduction
28
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
28
Cirrhosis II: Pathophysiology
42
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
42


